Date: 2013-02-21
Type of information:
Compound: novel medicines addressing unmet medical needs in Neuroscience and based on G-protein coupled receptor (GPCR) modulation
Company: UCB (Belgium) ConfometRx (USA)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: UCB has sealed a research agreement with ConfometRx to enable the discovery of novel medicines addressing unmet medical needs in Neuroscience. Under this two-year multi-target agreement, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs.
The terms of the agreement, whose details are not disclosed, include an up-front payment, Research funding and success-based milestones.
Financial terms:
Latest news:
